Hidradenitis Suppurativa

6-promising-bispecific-antibodies-beyond-oncology

Jun 10, 2025

5 Upcoming Bispecific & Trispecific Antibodies Beyond Oncology

top-7-hidradenitis-suppurativa-drug

Sep 13, 2024

7 Hidradenitis Suppurativa Drugs Set to Hit the Market in the Next 5 Years

hidradenitis-suppurativa-treatment

Sep 06, 2024

Could Hidradenitis Suppurativa Be Another Psoriasis?

Pharma News for Merck, AbbVie, Abbisko

Jan 09, 2024

Merck to Acquire Harpoon Therapeutics; Novo Nordisk Enters Into Collaborations with Omega Therapeutics and Cellarity; AbbVie’s Lutikizumab’s Phase II Trial Result for Hidradenitis Suppurativa; Abbisko’s CSF-1R Inhibitor Pimicotinib (ABSK021); Cabaletta Bio’s CABA-201; FDA Grants Fast Track” Designation for Soligenix’s Dusquetide

cosentyx-for-hidradenitis-suppurativa-treatment

Nov 24, 2023

Novartis Cosentyx: First Biologic Hidradenitis Suppurativa Treatment After Almost Ten Years

Delveinsight

Dec 13, 2022

Amgen to Purchase Horizon Therapeutics; IND Clearance to Vertex’s VX-522; FDA Fast-Track Designation for Moleculin’s WP1122; Orphan Drug Designation to Brim’s WP1122; Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study; UCB Announces Phase 3 Studies for Bimekizumab

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper